As of 2026-09-21, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -7.19. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,569.12 mil USD. RARE's TTM EBITDA according to its financial statements is -496.55 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.1x - 16.8x | 16.5x |
| Forward P/E multiples | 19.3x - 22.8x | 20.9x |
| Fair Price | (60.18) - (53.18) | (58.55) |
| Upside | -514.8% - -466.5% | -503.5% |
| Date | EV/EBITDA |
| 2026-09-18 | -7.19 |
| 2026-09-17 | -7.18 |
| 2026-09-16 | -6.61 |
| 2026-09-15 | -6.68 |
| 2026-09-14 | -6.87 |
| 2026-09-11 | -7.11 |
| 2026-09-10 | -7.15 |
| 2026-09-09 | -7.12 |
| 2026-09-08 | -7.32 |
| 2026-09-04 | -7.47 |
| 2026-09-03 | -7.31 |
| 2026-09-02 | -11.45 |
| 2026-09-01 | -11.19 |
| 2026-08-31 | -10.98 |
| 2026-08-28 | -11.12 |
| 2026-08-27 | -11.35 |
| 2026-08-26 | -11.42 |
| 2026-08-25 | -11.42 |
| 2026-08-24 | -11.16 |
| 2026-08-21 | -11.20 |
| 2026-08-20 | -11.02 |
| 2026-08-19 | -11.34 |
| 2026-08-18 | -11.08 |
| 2026-08-17 | -11.31 |
| 2026-08-14 | -11.43 |
| 2026-08-13 | -11.39 |
| 2026-08-12 | -11.56 |
| 2026-08-11 | -11.60 |
| 2026-08-10 | -11.54 |
| 2026-08-07 | -11.23 |
| 2026-08-06 | -11.20 |
| 2026-08-05 | -10.88 |
| 2026-08-04 | -11.19 |
| 2026-08-03 | -10.91 |
| 2026-07-31 | -10.87 |
| 2026-07-30 | -11.27 |
| 2026-07-29 | -10.91 |
| 2026-07-28 | -11.25 |
| 2026-07-27 | -11.57 |
| 2026-07-24 | -11.58 |
| 2026-07-23 | -11.62 |
| 2026-07-22 | -11.84 |
| 2026-07-21 | -12.19 |
| 2026-07-20 | -12.16 |
| 2026-07-17 | -12.42 |
| 2026-07-16 | -12.75 |
| 2026-07-15 | -13.28 |
| 2026-07-14 | -13.40 |
| 2026-07-13 | -13.82 |
| 2026-07-10 | -14.03 |